12

October

Selpercatinib (Retevmo®) Management

Written By: Joshua Nubla, PharmD, NCODA

Download Here

Description: This PQI is developed to provide guidance for management of patients treated with selpercatinib.

Background: Selpercatinib is a kinase inhibitor indicated for the treatment of:

  • Adult patients with metastatic RETfusion-positive non-small cell lung cancer (NSCLC)
  • Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
  • Adult and pediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *This indication is approved under accelerated approval based on overall response rate and duration of response.1

A multicohort study was conducted in patients with RET fusion-positive metastatic NSCLC, advanced or metastatic MTC, and RET point-mutation advanced or metastatic MTC. The major efficacy outcome, objective response rate (ORR) to selpercatinib was 64% in previously treated NSCLC. Median duration of response was 17.5 months and 63% of the responses were ongoing at a median follow-up of 12.1 months. For those who were previously untreated, ORR was measured at 85% (n=39).2 Efficacy in patients with RET-mutant MTC who were previously treated with cabozantinib and/or vandetanib was studied and ORR was 69% (n=55) and median duration of response was not reached despite a median follow-up of 14.8 months. In this same study, cabozantinib or vandetanib-naive patients had an ORR of 73% (n=88). RET fusion-positive thyroid cancer patients who were radioactive iodine (RAI)-refractory and were systemic therapy naïve had an ORR of 100% (CR 12.5%, PR 74%, n=8). Those thyroid patients previously treated with sorafenib, lenvatinib, or both had an ORR of 79% (CR 5.3%, PR 74%, n=19).3 Permanent discontinuation due to adverse reactions occurred in 5% of patients who have received selpercatinib. Dosage reductions due to an adverse reaction occurred in 31% of patients and the reactions where at least 2% or more of patients required reduction included ALT increased, AST increased, QT prolongation and fatigue.

PQI Process:

  • Determine if a patient is eligible for selpercatinib

Upon prescription of selpercatinib

  • Confirm Correct Dosing
    • Recommended dosage in adults and pediatric patients 12 years of age or older is based on weight
      • Less than 50 kg: 120 mg orally twice daily
      • 50 kg or greater: 160 mg orally twice daily

 Dosing considerations for Adverse Reactions

Recommended Selpercatinib Dose Reductions for Adverse Reactions1
Dose ReductionPatients Weighing Less Than 50 kgPatients Weighing 50 kg or Greater
First80 mg orally twice daily120 mg orally twice daily
Second40 mg orally twice daily80 mg orally twice daily
Third40 mg orally once daily40 mg orally twice daily

Permanently discontinue if patient is unable to tolerate three dose reductions

Recommended Selpercatinib Dose Reductions for Adverse Reactions1

Adverse ReactionSeverityDosage Modification
HepatotoxicityGrade 3
or
Grade 4
·      Withhold selpercatinib and monitor AST/ALT once weekly until resolution to Grade 1 or baseline

·      Resume at reduced dose by 2 dose levels and monitor AST and ALT once weekly until 4 weeks after reaching dose taken prior to the onset of Grade 3 or 4 increased AST or ALT

·      Increase dose by 1 dose level after a minimum of 2 weeks without recurrence and then increase to dose taken prior to the onset of Grade 3 or 4 increased AST or ALT after a minimum of 4 weeks without recurrence

HypertensionGrade 3·      Withhold selpercatinib for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled
Grade 4·      Discontinue selpercatinib
QT Interval ProlongationGrade 3·      Withhold selpercatinib until recovery to baseline or Grade 0 or 1

·      Resume at a reduced dose

Grade 4·      Discontinue selpercatinib
Hemorrhagic EventsGrade 3
or
Grade 4
·      Withhold selpercatinib until recovery to baseline or Grade 0 or 1

·      Discontinue selpercatinib for severe or life-threatening hemorrhagic events

Hypersensitivity ReactionsAll Grades·      Withhold selpercatinib until resolution of the event. Initiate corticosteroids

·      Resume at a reduced dose by 3 dose levels while continuing corticosteroids

·      Increase dose by 1 dose level each week until the dose taken prior to the onset of hypersensitivity is reached, then taper corticosteroids

Other Adverse ReactionsGrade 3
or
Grade 4
·      Withhold selpercatinib until recovery to baseline or Grade 0 or 1

·      Resume at a reduced dose

 

 

 

Recommended Dosage for Concomitant Use of Strong and Moderate CYP3A Inhibitors

Current DosageRecommended Dosage
Moderate CYP3A InhibitorStrong CYP3A Inhibitor
120 mg orally twice daily80 mg orally twice daily40 mg orally twice daily
160 mg orally twice daily120 mg orally twice daily80 mg orally twice daily

 

Recommended Dosage for Severe Hepatic Impairment
Current DosageRecommended Dosage
120 mg orally twice daily80 mg orally twice daily
160 mg orally twice daily80 mg orally twice daily

 

Patient Centered Activities:

  • Provide Oral Chemotherapy Education (OCE) sheet
  • Counsel patient to swallow the capsules whole with or without food and to not crush/chew the capsules
  • Review patient medication list to avoid concomitant use of strong and moderate CYP3A inhibitors
  • Counsel patient to report adverse events related to high blood pressure, liver problems, heart rhythm changes, signs of bleeding, allergic reactions, and lack of wound healing
  • Tumor lysis syndrome (TLS) occurred in 1% of patients with medullary thyroid carcinoma receiving selpercatinib
    • Counsel patient to contact care team to report signs and symptoms of TLS4
      • Nausea
      • Vomiting
      • Lack of appetite
      • Fatigue
      • Dark urine/flank pain
      • Reduced urine output
      • Numbness, seizures, hallucinations
      • Muscle cramps
      • Heart palpitations 

References:

  1. RETEVMO ® [package insert]. Lilly USA, LLC, Indianapolis, IN.
  2. Drilon A, Oxnard GR, et al. Efficacy of Selpercatinib in RETFusion–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2020; 383:813-824.
  3. Shah MH, Sherman EJ, et al. Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer. J Clin Oncol. 2020; 38 (15).
  4. Gupta A, Moore JA. Tumor Lysis Syndrome. JAMA Oncol. 2018;4(6):895.
Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional.  This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented.  NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
Victoria

Victoria has blogged 1620 posts

View all PQI